LINC00677: A Potential Drug Target and Biomarker (G105370683)

Target Name: LINC00677

NCBI ID: G105370683

LINC00677

Other Name(s): Long intergenic non-protein coding RNA 677 | long intergenic non-protein coding RNA 677 | C14orf74

LINC00677: A Potential Drug Target and Biomarker

Long intergenic non-protein coding RNAs (lncNPs) have emerged as a promising candidate for drug discovery and development due to their diverse functions and potential to disrupt gene expression networks. In this article, we will focus on LINC00677, a well-validated lncNP that has the potential to serve as a drug target or biomarker.

LINC00677 is a transcribed RNA molecule that has been identified in various organisms, including humans. It is characterized by a unique 5'-end structure, which consists of a 7-nt stem-loop followed by a 3'-end exon. Despite its small size, LINC00677 has a significant impact on gene expression patterns in various organisms.

Several studies have demonstrated that LINC00677 can interact with various protein molecules and play a role in regulating gene expression. For instance, LINC00677 has been shown to physically interact with the protein encoded by the SIRT3 gene, which is a key regulator of DNA repair and longevity . Additionally, LINC00677 has been shown to enhance the translation efficiency of RNA polymerase II, a critical enzyme involved in gene expression.

Furthermore, LINC00677 has been linked to various diseases, including cancer, neurodegenerative diseases, and psychiatric disorders. For example, studies have shown that LINC00677 is highly expressed in breast cancer tissues and is associated with poor prognosis. Additionally, LINC00677 has been shown to be Abnormally expressed in neurodegenerative diseases, such as Alzheimer's disease and Parkinson's disease.

Given the potential implications of LINC00677's role in disease, it is encouraging that researchers have identified a potential drug target for this RNA molecule. The therapeutic potential of LINC00677 is high, as it has been shown to interact with multiple proteins and to play a role in regulating gene expression.

In addition to its potential as a drug target, LINC00677 also has the potential to serve as a biomarker for various diseases. Its expression patterns can be used as a diagnostic tool for diseases, such as cancer, neurodegenerative diseases, and psychiatric disorders. Additionally, LINC00677's expression levels can be used as a target for drug intervention, as therapeutic compounds can be designed to specifically target LINC00677 to enhance its expression levels and improve disease outcomes.

In conclusion, LINC00677 is a well-validated lncNP that has the potential to serve as a drug target or biomarker. Its unique 5'-end structure and its interaction with multiple proteins make it an attractive candidate for drug discovery. Additionally, its association with various diseases and its potential as a diagnostic and therapeutic tool make it an exciting area of ??????research.

Overall, LINC00677 is a promising candidate for drug discovery and development, and its unique properties make it an attractive target for researchers to investigate further. Further studies are needed to fully understand the functional implications of LINC00677 and its potential as a drug and biomarker.

Protein Name: Long Intergenic Non-protein Coding RNA 677

The "LINC00677 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about LINC00677 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets